Safety, Tolerability and Pharmacokinetics of Oral Doses of RP3128 of Rhizen Pharmaceuticals

Inclusion Criteria: * Male and non-childbearing female subjects (SAD/MAD) and male and non-childbearing female patients with mild asthma; * Healthy subjects as determined by past medical history, vitals, physical examination and 12-lead ECG, clinical laboratory tests. * Body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive, weight ≥50 kg; * Non-smokers or ex-smokers * Willingness to adhere to the protocol requirements as evidenced by the informed consent form (ICF) duly read, signed and dated by the subject; able to comply with protocol requirements and or study procedure; * Negative screen for drugs of abuse and alcohol at screening and on admission. * Male subjects should agree not to donate sperm for 3 months post dose; and * Female partners (of child bearing potential) of male subjects should use 2 methods of highly effective contraception for 3 months post last Additionally for POC * Pre- bronchodilator Forced expiratory volume in 1 sec( FEV1) of \> 70% (adjusted for age, sex and race) * Steroid naïve subjects with history of mild asthma that satisfy the Global Initiative for Asthma (GINA) definition of asthma, but otherwise healthy. Exclusion Criteria: * Subjects with evidence or history of clinically significant medical history. * History of tuberculosis (TB) and/or a positive Tuberculin Skin Test and/or QuantiFeron- TB®-Gold test. * Use of any immunotherapy within 3 months prior to screening. * History of serious adverse reaction, severe hypersensitivity or allergy to any drug/drug substance (except house dust mite, pollen allergens or cat dander allergy in asthmatics) or in any other circumstance (e.g. anaphylaxis); * Abnormal liver function * Positive screen on hepatitis-B surface antigen (HBsAg), antibodies to the hepatitis C (HCV) or antibodies to the human immunodeficiency virus (HIV) 1,2;